- Home
- BDTX vs ECOR Comparison
BDTX vs ECOR Comparison
Compare BDTX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | ECOR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 100.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BDTX | ECOR |
|---|---|---|
| Price | $1.84 | $8.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $10.00 | ★ $19.17 |
| AVG Volume (30 Days) | ★ 857.5K | 72.9K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $30.85 |
| Revenue Next Year | N/A | $29.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $1.60 | $4.41 |
| 52 Week High | $4.94 | $12.70 |
Technical Indicators
Market Signals| Indicator | BDTX | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 44.83 |
| Support Level | $1.83 | $5.59 |
| Resistance Level | $1.93 | $10.60 |
| Average True Range (ATR) | 0.15 | 0.69 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 43.52 | 46.04 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.